Department of ophthalmology, Institute Of Medical Sciences, BHU, Varanasi
*Corresponding Author: E-mail: sunnymbbs2007@gmail.com
Online published on 13 May, 2015.
To evaluate which factors influence maximum gain in best-corrected visual acuity after intravitreal injection of Bevacizumab as treatment for diffuse diabetic macular edema.
This was a prospective, interventional trial including 112 eyes of 100 participants. Visual outcomes measured by change in visual acuity (VA) score, proportion gaining ≥15 letters, and change in central retinal thickness (CRT), presence of macular ischaemia, IS/OS integrity.
Mean change in the VA score was 9.2 ± 2.3 SD letters with a total of 79 eyes gaining ≥15 letters. Change in median CRT was 81.5 μm. Younger age, higher baseline VA score, shorter duration of Diabetic Macular Edema (DME), absence of macular ischemia and an intact IS/OS junction were significantly associated with greater VA score improvement.
Pronounced macular edema and intact IS/OS junction may have a positive impact, and marked macular ischemia and a high preoperative best-corrected visual acuity may have a negative impact, on an increase in best-corrected visual acuity after intravitreal Bevacizumab injection in patients with diabetic macular edema.
Bevacizumab, Diabetic macular edema, IS/OS junction, Macular ischaemia
